Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans.
Acta Pharmacol Sin
; 43(2): 494-503, 2022 Feb.
Article
in En
| MEDLINE
| ID: mdl-33927359
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antineoplastic Agents
Type of study:
Prognostic_studies
Limits:
Adult
/
Animals
/
Female
/
Humans
/
Male
Language:
En
Journal:
Acta Pharmacol Sin
Journal subject:
FARMACOLOGIA
Year:
2022
Document type:
Article
Affiliation country:
China
Country of publication:
Estados Unidos